Table 3 Target mRNA levels in 2 NSCLC xenografts after bevacizumab treatment
NSCLC#3 | NSCLC#5 | ||||||
|---|---|---|---|---|---|---|---|
Control (n=5) | After bevacizumab reatment (n=5) | p-value 1 | Control (n=5) | After bevacizumab treatment (n=5) | p-value 1 | ||
PECAM1/CD31 mRNA | Human | 18.1 (7.34-43.1) | 57.6 (31.8-64.2) | <0.05 | 2.38 (0.00-9.21) | 6.70 (2.41-17.1) NS | |
Mouse | 863 (686-1790) | 578 (483-847) | <0.05 | 2 334 (1 538-4 363) | 856 (699-980) | <0.05 | |
ENG/CD105 mRNA | Human | 29.1 (3.59-47.2) | 38.2 (15.1-71.4) | NS | 57.64 (38.8-90.86) | 57.50 (47.2 - 84.4) | NS |
Mouse | 619 (580-1098) | 414 (328-619) | <0.05 | 1 519 (1120-1813) | 821 (610-860) | <0.05 | |
FLT1/VEGFR1 mRNA | Human | 59.6 (56.7-90.6) | 88.9 (62.3-118) | NS | 3.84 (0.00-24.8) | 9.11 (3.87-20.3) | NS |
Mouse | 589 (470-909) | 274 (212-362) | <0.05 | 938 (633-1163) | 305 (216-344) | <0.05 | |
KDR/VEGFR2 mRNA | Human | 507 (361-622) | 545 (488-643) | NS | 220 (140-274) | 574 (213-834) | NS |
Mouse | 466 (386-800) | 204 (196-298) | <0.05 | 1 175 (698-1 211) | 328 (316-349) | <0.05 | |
VEGFA mRNA | Human | 20 503 (19162-24600) | 32 160 (30 331-35 680) | <0.05 | 11 984 (5 368-13 961) | 12 235 (7 088-14 042) | NS |
Mouse | 160 (119-495) | 307 (184-614) | NS | 262 (170-680) | 267 (240-360) | NS | |